PG-116800

**PG-116800** is an orally active, small molecule inhibitor of matrix metalloproteinases (MMPs), specifically designed to target MMP subtypes implicated in tissue remodeling and degradation. It belongs to the hydroxyproline-based hydroxamic acid class of MMP inhibitors and exhibits high affinity for MMP-2, -3, -8, -9, -13, and -14. The drug was developed by Procter & Gamble Pharmaceuticals primarily for the treatment of osteoarthritis (OA) and also investigated for its potential to reduce left ventricular remodeling after myocardial infarction (MI). Despite promising preclinical antiremodeling effects in animal models of MI and ischemic heart failure, clinical trials failed to demonstrate efficacy in patients with knee OA or post-MI cardiac remodeling. Notably, higher doses were associated with musculoskeletal adverse effects such as arthralgia and joint stiffness[2][3][5][6][7][8].

Other names

291533-11-4UNII-F94T42GL80UNII-F-94T42GL80UNII-F 94T42GL80